Sitagliptin

Sitagliptin is a DPP‑4 inhibitor with modest HbA1c reduction and cardiovascular neutrality; it has no demonstrated heart failure outcome benefit. DPP-4 inhibitors may in fact exacerbate heart failure symptoms through oedema worsening. This is not the best drug for Mr. Green.

Please go back and re-consider. 

  • Σταματάει προς το παρόν την ψυχοθεραπεία [undo]
  • Εξοδος απο το Νοσοκομειο [undo]
  • Descripción 2 [undo]
  • Epilogue [undo]
  • Lispro [undo]
  • Enalapril (ACE inhibitor) [undo]
  • NOACs are safer than warfarin. The answer is correct. [undo]
  • Ca să nu rupem sau murdărim halatul în afara laboratorului [undo]
  • Setting up the reaction [undo]
  • Συμπεράσματα [undo]
  • Εξοπλισμός εργαστηριακής ασφάλειας [undo]
  • To stabilize the DNA double helix structure, ensuring precise cleavage [undo]
  • To enhance the binding affinity of restriction endonucleases to non-specific sequences [undo]
  • Sitagliptin [undo]

Map: Michael Green_GEMD_1 (1115)
Node: 21101
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway